Literature DB >> 17245081

Intravitreal triamcinolone acetonide for diabetic retinopathy.

Jost B Jonas1.   

Abstract

Intravitreal triamcinolone acetonide (IVTA) has been applied in exponentially increasing frequency for various intraocular neovascular and edematous diseases, including diabetic macular edema, proliferating diabetic retinopathy, neovascular glaucoma due to proliferative diabetic retinopathy, and chronic prephthisical ocular hypotony as complication of the surgical treatment of diabetic retinopathy. In diabetic macular edema, the edema may almost completely resolve, and visual acuity may increase as much as macular ischemia and the tissue destruction by the diabetic process may allow. For proliferative diabetic retinopathy and neovascular glaucoma, investigations have suggested an antiangiogenic effect of IVTA. Using a side effect of IVTA, i.e. steroid-induced elevation of intraocular pressure, IVTA may be applied for the therapy of chronic prephthisical ocular hypotony due to an insufficiency of the ciliary body as consequence of a surgical treatment of proliferative diabetic retinopathy. The complications of IVTA include secondary ocular hypertension in about 40% of the eyes, medically uncontrollable high intraocular pressure leading to antiglaucomatous surgery in about 1-2%, posterior subcapsular cataract and nuclear cataract leading to cataract surgery in about 15-20%, especially in elderly patients within 1 year after injection, postoperative infectious endophthalmitis with a rate of about 1:500 or 1:1,000, noninfectious endophthalmitis, and pseudo-endophthalmitis. IVTA can be combined with other intraocular surgeries including cataract surgery, particularly in eyes with iris neovascularization due to diabetic retinopathy. Cataract surgery performed some months after the injection does not show a markedly elevated rate of complications. If vision increases and eventually decreases after an IVTA injection, the injection can be repeated. The duration of the effect of a single IVTA is dosage dependent (about 6-9 months with 20 mg, and about 2-4 months with 4 mg).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245081     DOI: 10.1159/000098502

Source DB:  PubMed          Journal:  Dev Ophthalmol        ISSN: 0250-3751


  15 in total

Review 1.  Diabetic complications in the cornea.

Authors:  Alexander V Ljubimov
Journal:  Vision Res       Date:  2017-04-28       Impact factor: 1.886

Review 2.  Current approaches to the management of diabetic retinopathy and diabetic macular oedema.

Authors:  Francesco Boscia
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

Review 3.  Diabetic retinopathy: Early diagnosis and effective treatment.

Authors:  Aris N Kollias; Michael W Ulbig
Journal:  Dtsch Arztebl Int       Date:  2010-02-05       Impact factor: 5.594

Review 4.  The Therapeutic Role of Carotenoids in Diabetic Retinopathy: A Systematic Review.

Authors:  Mohammad Fathalipour; Hadis Fathalipour; Omid Safa; Peyman Nowrouzi-Sohrabi; Hossein Mirkhani; Soheil Hassanipour
Journal:  Diabetes Metab Syndr Obes       Date:  2020-07-03       Impact factor: 3.168

5.  Diabetic retinopathy - An update.

Authors:  Abdulrahman A Alghadyan
Journal:  Saudi J Ophthalmol       Date:  2011-01-31

Review 6.  Clinical trials on corticosteroids for diabetic macular edema.

Authors:  Hassan A Al Dhibi; J Fernando Arevalo
Journal:  World J Diabetes       Date:  2013-12-15

7.  Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema.

Authors:  Ju Hwan Song; Jung Joo Lee; Sang Joon Lee
Journal:  Korean J Ophthalmol       Date:  2011-05-24

8.  Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits.

Authors:  Zhengyu Song; Yuanyuan Gong; Haiyun Liu; Qiushi Ren; Xiaodong Sun
Journal:  Mol Vis       Date:  2011-08-04       Impact factor: 2.367

Review 9.  Cellular signaling and potential new treatment targets in diabetic retinopathy.

Authors:  Zia A Khan; Subrata Chakrabarti
Journal:  Exp Diabetes Res       Date:  2007

Review 10.  Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.

Authors:  Timothy S Kern
Journal:  Exp Diabetes Res       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.